PsA pts have ^ risk of developing polyclonal gammopathy, MGUS, and possibly progression to lymphoproliferative malignancy. #ABS0338 #ACR20 @RheumNow https://t.co/jl6sq1KcKZ https://t.co/BHrGKPXs3a

• Increased Risk of Lymphoproliferative Disorders in Psoriatic Arthritis - ACR Me…

#GREATDEBATE Dr. Weinblatt won - but based on the limited # people polled d/t difficulties with website #ACR20 @RheumNow

Do you screen your PsA patients for lymphoproliferative disease? @RheumNow #ACR20 #ABS0338

Dr. G Gilkeson #Klempererlecture #ACR20 @rheumnow There is a lupus gradient b/t Africa and US: we are seeing more SLE in the US (genetics? environmental? diet?)

The Great Debate results! https://t.co/tJk0yIRqfK

Since you’ve just listened to The Great Debate, what do you use as your first line therapy in RA #ACR20? @RheumNow

MTX & liver fibrosis: 71% pts w/low FIB-4i of<1.45 No correlation bet FIB-4 values & cumulative MTX dose Cumulative MTX dose not sig. ⬆ in pts with FIB-4i >1.45 @RheumNow #ACR20 Abstr#0205 https://t.co/RmyAz9M5fw

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by BMS, @HorizonNews , @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.

How well do your RA patients sleep? Is OSA an issue? Validated questionnaires and clinician questioning missed two-thirds (23/35) of mod-severe OSA, no clues from steroid use or RA disease activity. Should we be screening more patients? @UCSFHospitals #ACR20 ABST0196 @RheumNow https://t.co/kibwDPYYn9

Abst#0138 at #ACR20 shows the importance of identifying alignments & discordances in perceptions of RA tx between providers & patients, individualizing txs accordingly, & a need to engage in shared-decision making to optimize RA care. @RheumNow https://t.co/dTj0S7Zm5x

Dr. Gilkerson in 2F010- Lupus in Unusual Places at #ACR20- Is it environmental or genetics that explain differences between African and African-Amer populations? Study the population (Sierra Leone), but do so with cultural sensitivity. @RheumNow https://t.co/B1ikkQgCuk

How would you change csDMARDS and bDMARDS a few days before vaccination - if/when #COVID19 KILLED vaccine comes in (Assuming live vaccine would need strict medication management.) #ACR20 @RheumNow

DVT/PE has been the sticking point for baricitinib in RA. DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either. Every drug has pros/cons; it's how we manage risk that counts... #ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ

"Anatomy of the enthesis" #SpA #ACR20 https://t.co/uUeCWGXqtw